Michael Kinch

The End of the Beginning (eBook, ePUB)

• Format: ePub

Produktbeschreibung

For the first time since a 5th century Greek physician gave the name "cancer" (karkinos, in Greek) to a deadly disease first described in Egyptian Papyri, the medical world is near a breakthrough that could allow even the most conservative doctors and pragmatic patients to use the other "c word" cure in the same sentence as cancer. A remarkable series of events has brought us to this point, thanks in large part to a new ability to more efficiently harness the extraordinary power of the human immune system.The End of the Beginning is a remarkable history of cancer treatment and the evolution of our understanding of its dynamic interplay with the immune system. Through Michael Kinch's personal experience as a cancer researcher and the head of the oncology program at a leading biotechnology company, we witness the incredible accumulation of breakthrough science and its rapid translation into life-saving technologies that have begun to dramatically increase the quality and quantity of life for cancer patients. In clear and accessible prose, Kinch details the remarkable history of people, science, technology and disease and presents thrilling next-generation technologies that hold the promise to eliminate cancer for some, and perhaps ultimately, for all.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Simon + Schuster LLC
• Seitenzahl: 336
• Erscheinungstermin: 2. April 2019
• Englisch
• ISBN-13: 9781643131085
• Artikelnr.: 58750632

Autorenporträt

Michael Kinch is a professor at Washington University in St. Louis. He is the author of Between Hope and Fear (Pegasus Books), The End of the Beginning (Pegasus Books) and A Prescription for Change (UNC Press). Beyond his current work documenting the sources of innovation responsible for new medicines, he has led cancer research activities at the biotechnology company MedImmune and the development of medicines to prevent pandemic virus outbreaks at Functional Genetics, Inc. He led drug discovery at Yale University before moving to St Louis.